2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Lymphoma
225
Lymphoma, Large B-Cell, Diffuse
160
Small Cell Lung Carcinoma
156
Precursor Cell Lymphoblastic Leukemia-Lymphoma
143
Lymphoma, Non-Hodgkin
139
Leukemia
135
Leukemia, Myeloid, Acute
117
Hodgkin Disease
106
Lung Neoplasms
99
Burkitt Lymphoma
99
Lymphoma, Follicular
85
Lymphoma, Mantle-Cell
76
Lymphoma, Large-Cell, Immunoblastic
68
Carcinoma, Non-Small-Cell Lung
61
Neuroblastoma
60
Leukemia, Lymphocytic, Chronic, B-Cell
56
Recurrence
53
Multiple Myeloma
52
Lymphoma, B-Cell, Marginal Zone
43
Congenital Abnormalities
43
Sarcoma
39
Central Nervous System Neoplasms
39
Myelodysplastic Syndromes
35
Brain Neoplasms
34
Ovarian Neoplasms
32
Leukemia, Myelomonocytic, Acute
32
Lymphoma, B-Cell
31
Leukemia, Monocytic, Acute
31
Leukemia, Erythroblastic, Acute
31
Testicular Neoplasms
30
Interventions
Magnetic Resonance Spectroscopy
7
X-Rays
6
Specimen Handling
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
5
Biopsy
5
trametinib
3
fludarabine
3
dabrafenib
3
Tacrolimus
3
Melphalan
3
Cyclophosphamide
3
Busulfan
3
ulixertinib
2
tipifarnib
2
thymoglobulin
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
fludarabine phosphate
2
erdafitinib
2
ensartinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Rituximab
2
Mycophenolic Acid
2
LY3023414
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytosis, Langerhans-Cell
×
Etoposide
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled